1. Scrip

AIRNA To Take RNA Editing Into The Clinic With $155m Series B Round

Previously Raised $90m In Series A Cash

 
• By Mandy Jackson

CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.

(Shutterstock)
Key Takeaways
  • AIRNA closed a $155m series B round to take its first RNA editing medicine into the clinic for the treatment of AATD. The firm will also continue building its technology platform and R&D pipeline.
  • The start-up launched in 2023 with a $30m series A round that grew to $90m in 2024 based on RNA editing research from co-founders at the University of Tübingen and Stanford University.
  • AIRNA’s technology can edit RNA to repair harmful genetic variants or produce variants that confer health benefits, which may offer treatment potential in large indications.

AIRNA Therapeutics soon will test its novel RNA editing approach in patients for the first time, starting with the rare genetic disease alpha-1 antitrypsin deficiency (AATD), but the company is...

Cambridge, MA-based AIRNA launched in 2023 with $30m in initial cash and expanded the series A round to $90m in July 2024 with

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Scrip

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.